Moderna (NASDAQ:MRNA) Lifted to "Hold" at Hsbc Global Res

Hsbc Global Res upgraded shares of Moderna (NASDAQ:MRNA - Free Report) from a moderate sell rating to a hold rating in a research note issued to investors on Wednesday morning, Zacks.com reports.

MRNA has been the subject of a number of other research reports. Evercore ISI restated an in-line rating and set a $120.00 price objective on shares of Moderna in a research note on Thursday, June 27th. The Goldman Sachs Group lowered their price objective on Moderna from $204.00 to $178.00 and set a buy rating for the company in a research note on Friday, August 2nd. Canaccord Genuity Group raised their price objective on Moderna from $91.00 to $106.00 and gave the company a hold rating in a research note on Friday, May 3rd. Needham & Company LLC restated a hold rating on shares of Moderna in a research note on Thursday, August 1st. Finally, Oppenheimer raised their price objective on Moderna from $163.00 to $179.00 and gave the company an outperform rating in a research note on Wednesday, June 12th. Ten analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of Hold and an average target price of $123.79.

Moderna Stock Down 1.0 %

Shares of MRNA stock traded down $0.77 during trading hours on Wednesday, reaching $77.59. The company had a trading volume of 3,307,062 shares, compared to its average volume of 4,086,561. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.91 and a current ratio of 4.09. Moderna has a twelve month low of $62.55 and a twelve month high of $170.47. The company has a market capitalization of $29.74 billion, a P/E ratio of -4.96 and a beta of 1.67. The stock's fifty day simple moving average is $106.87 and its 200 day simple moving average is $113.12.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. During the same quarter last year, the firm earned ($3.62) earnings per share. The company's revenue for the quarter was down 29.9% compared to the same quarter last year. As a group, sell-side analysts expect that Moderna will post -7.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO James M. Mock sold 689 shares of the firm's stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the sale, the chief financial officer now owns 7,269 shares of the company's stock, valued at approximately $859,486.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CFO James M. Mock sold 689 shares of the firm's stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the sale, the chief financial officer now owns 7,269 shares of the company's stock, valued at approximately $859,486.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO James M. Mock sold 1,321 shares of the firm's stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 330,274 shares of company stock valued at $46,294,062. Insiders own 15.70% of the company's stock.

Institutional Trading of Moderna

Hedge funds have recently added to or reduced their stakes in the business. Ashton Thomas Private Wealth LLC bought a new stake in Moderna during the 2nd quarter valued at $26,000. Ogorek Anthony Joseph NY ADV bought a new stake in Moderna during the 4th quarter valued at $27,000. Family Firm Inc. bought a new stake in Moderna during the 2nd quarter valued at $33,000. Cedar Wealth Management LLC raised its stake in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company's stock valued at $31,000 after acquiring an additional 90 shares in the last quarter. Finally, Westside Investment Management Inc. bought a new stake in Moderna during the 1st quarter valued at $32,000. Institutional investors own 75.33% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.